Connect with us

Hi, what are you looking for?

Jewish Business News

Court

Teva Settles Patent Litigation with Pfizer on arthritis treatment Celebrex


Brand Celebrex has $2.2 billion in US sales in 2013, according to IMS data.

images

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer Inc. (NYSE: PFE; LSE: PFZ) , related to Pfizers arthritis drug Celebrex capsules and Teva’s generic version of Celebrex (celecoxib) capsules.

Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Sales of Celebrex® were $2.2 billion in the U.S. according to IMS data as of December, 2013.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Business

Now Platika joins and elite club of $10 billion plus Israeli firms.

Advertisement
cialis